article thumbnail

Former Teva Pharmaceutical Procurement Leader Joins Synovos

Synovos

3, 2019 – Thomas Cummins, former Global Head of Manufacturing Goods and Services Procurement for Teva Pharmaceuticals, has been named Senior Direct of Global Procurement for Synovos, the leading independent integrated supply chain management company in North America. in Whitehouse Station, NJ, before moving to Teva in 2014.

article thumbnail

Supply Chain Best Practices: Preparing for the Worst

Elementum

Potential Sources of Disruption. Identifying sources of risk and developing a plan are only part of the story. What alternative plants/factories/sources of supply do they have at their disposal? Unplanned IT or telecommunications outage. Cyberattack and data breach. Loss of talent/skills. Outsourcer failure. Weather event.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Supply Chain Best Practices: Preparing for the Worst

Elementum

Potential Sources of Disruption. Identifying sources of risk and developing a plan are only part of the story. What alternative plants/factories/sources of supply do they have at their disposal? Unplanned IT or telecommunications outage. Cyberattack and data breach. Loss of talent/skills. Outsourcer failure. Weather event.

article thumbnail

Anita Arts: “A supply chain manager can no longer sit in an ivory tower

Supply Chain Movement

The British company is owner of Unitymedia KabelBW (Germany), UPC (The Netherlands, Republic of Ireland, Poland, Czech Republic, Slovakia, Switzerland, Austria, Hungary and Romania), VTR (Chile) and Liberty (Puerto Rico). because there are only three major companies left who manufacturer such chipsets.”.

article thumbnail

Record High Drug Shortages in the U.S.- Same Dysfunctional Problem

Supply Chain Matters

That number is the highest reported since 2014, including the period of the Covid-19 pandemic during the years 2020 to 2023. It has to do with middlemen who have made manufacturing generic injectable drugs unprofitable, magnifying the risk of shortages by artificially reducing supply.”